Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Gene Therapy Study Participant Maintains HIV Viral Suppression Off ART, Sangamo Says

A patient who received genetically modified CD4 T-cells lacking a co-receptor that enables HIV entry has maintained undetectable viral load during an antiretroviral treatment interruption lasting 14 weeks, according to a presentation at the annual meeting of the European Society of Gene and Cell Therapy taking place this week in Madrid.

alt

Read more:

EACS 2013: Once-daily Raltegravir Effective as Maintenance Therapy; New Formulation in Development

Almost all HIV positive people with undetectable viral load who switched to once-daily raltegravir (Isentress) maintained viral suppression, French researchers reported at the 14thEuropean AIDS Conference this month in Brussels. In an effort to facilitate once-daily dosing, Merck is working on a new tablet that appears less affected by food than the current formulation.

alt

Read more:

ViiV Requests FDA Approval for Dolutegravir Single-tablet Regimen for HIV

ViiV Healthcare announced this week that it has submitted a New Drug Application for U.S. Food and Drug Administration (FDA) approval of a new all-in-1 pill containing the HIV integrase inhibitor dolutegravir (brand name Tivicay) plus abacavir and lamivudine (the drugs in Epzicom).

alt

Read more:

Researchers Publish Case Report of Mississippi Baby Cured of HIV

The case report of a child who remains free of detectable HIV more than 18 months after interrupting combination antiretroviral therapy (ART) that had been started within 2 days after birth has now been published in the New England Journal of Medicine. Experts have called this accidental experiment "proof-of-concept" that very early treatment may be able to cure HIV in some individuals.

alt

Read more:

EACS 2013: Future HIV Care Will Include Novel Drugs and New Treatment Strategies

HIV treatment in the coming years will include novel antiretroviral agents and new formulations such as long-acting injectables, as well as new strategies aimed at improving adherence and minimizing side effects, according to a lecture at last week at the 14th European AIDS Conference in Brussels.

alt

Read more:

EACS 2013: Dolutegravir Matches or Beats Other Antiretrovirals for First-line HIV Treatment

The recently approved HIV integrase inhibitor dolutegravir (Tivicay) provides at least equivalent antiviral efficacy and better tolerability compared with approved antiretroviral drugs for treatment-naive people, according to data reported at the 14th European AIDS Conference last week in Brussels and in the current edition of Lancet Infectious Diseases.

alt

Read more:

EACS 2013: Ensuring Good Quality HIV Care in Europe: Where Can We Improve?

Only 20% of people with HIV in Europe have fully suppressed viral load, compared to an estimated 24% in sub-Saharan Africa, despite much higher rates of HIV diagnosis in the European region, Professor Jens Lundgren of the University of Copenhagen told the 14th European AIDS Conference in Brussels on Saturday.

alt

Read more: